Video
Journals
Specialty Area
Topics
Institute for Value-Based Medicine
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Advertisement
Contact Info
2 Commerce Drive
Cranbury, NJ 08512
© 2025 MJH Life Sciences
AJMC®
All rights reserved.
AJMC®
All rights reserved.
Social Determinants of Health
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Panelists discuss how social determinants such as access, income, and literacy drive disparities in LDL-C control.
EP: 1.Understanding the Current State of LDL-C Goal Attainment and Barriers to Adequate Control in Hyperlipidemia
EP: 2.Challenges with Undertreatment in Hyperlipidemia and Opportunities to Address this Gap
EP: 3.Pharmacy-Driven Challenges
EP: 4.Real-World Insights and PROMPT-LIPID
EP: 5.Social Determinants of Health
EP: 6.The 2013 Guideline Shift
Panelists discuss how social determinants of health profoundly shape cholesterol control and patient engagement. Income, access to transportation, education, and health care coverage all influence adherence to low-density lipoprotein (LDL)–lowering therapy.
They emphasize that patients facing economic hardship are less likely to fill prescriptions, attend follow-up visits, or afford nonstatin agents. Cultural and language barriers further complicate communication around risk and treatment.
Panelists advocate for patient-centered strategies that integrate social support, care navigation, and community-based screening programs to reduce disparities in LDL cholesterol management.
Clinical Setting of Initial Psychotic Spectrum Disorder Diagnoses in an Integrated Health System
November 14th 2025This study examines the clinical settings of first-time psychotic spectrum disorder diagnoses in an integrated health system.
Read More
Inside the Discovery That Changed CML Treatment Forever with Jorge Cortes, MD
November 11th 2025Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival.
Listen
Gas-Permeable Contact Lenses Provide Superior VA in Children After Surgery
November 13th 2025Children who undergo primary congenital glaucoma surgery had better visual acuity (VA) when wearing contact lenses compared with spectacles.
Read More
Managed Care Cast Presents: Leveraging Topical Therapies for Pediatric Atopic Dermatitis
October 30th 2025Experts discuss how topical therapies effectively manage atopic dermatitis in pediatric patients, enhancing outcomes and addressing unique challenges.
Listen
Eosinophilia Linked With Immune-Related Adverse Events in NSCLC Treatment
November 9th 2025Eosinophilia serves as a significant biomarker for predicting immune-related adverse events in NSCLC patients treated with immune checkpoint inhibitors.
Read More
Oral PCSK9 Inhibitor Enlicitide Matches Injectables in Lowering LDL Cholesterol
November 8th 2025In a phase 3 trial, the investigational oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by nearly 60% in adults with or at risk for ASCVD.
Read More
Clinical Setting of Initial Psychotic Spectrum Disorder Diagnoses in an Integrated Health System
November 14th 2025This study examines the clinical settings of first-time psychotic spectrum disorder diagnoses in an integrated health system.
Read More
Inside the Discovery That Changed CML Treatment Forever with Jorge Cortes, MD
November 11th 2025Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival.
Listen
Gas-Permeable Contact Lenses Provide Superior VA in Children After Surgery
November 13th 2025Children who undergo primary congenital glaucoma surgery had better visual acuity (VA) when wearing contact lenses compared with spectacles.
Read More
Managed Care Cast Presents: Leveraging Topical Therapies for Pediatric Atopic Dermatitis
October 30th 2025Experts discuss how topical therapies effectively manage atopic dermatitis in pediatric patients, enhancing outcomes and addressing unique challenges.
Listen
Eosinophilia Linked With Immune-Related Adverse Events in NSCLC Treatment
November 9th 2025Eosinophilia serves as a significant biomarker for predicting immune-related adverse events in NSCLC patients treated with immune checkpoint inhibitors.
Read More
Oral PCSK9 Inhibitor Enlicitide Matches Injectables in Lowering LDL Cholesterol
November 8th 2025In a phase 3 trial, the investigational oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by nearly 60% in adults with or at risk for ASCVD.
Read More